SURG-27 COMPLETE RESECTION OF CONTRAST ENHANCING TUMOR VOLUME IS ASSOCIATED WITH IMPROVED SURVIVAL IN RECURRENT GLIOBLASTOMA - RESULTS FROM THE DIRECTOR TRIAL

Ítems similars

• Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial
  per: Suchorska, Bogdana, et al.
  Publicat: (2016)
• ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL
  per: Wirsching, Hans-Georg, et al.
  Publicat: (2018)
• P04.27 Texture feature analysis to predict overall survival in recurrent glioblastoma treated in the DIRECTOR trial
  per: Vils, A., et al.
  Publicat: (2017)
• NIMG-54. DIFFUSE TUMOR GROWTH PATTERN IS ASSOCIATED WITH WORSE OUTCOME ONLY IN IDH WILDTYPE BUT NOT IN IDH MUTANT GLIOMAS WHO II AND III
  per: Weller, Jonathan, et al.
  Publicat: (2020)
• AI-28 RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB
  per: Tabatabai, Ghazaleh, et al.
  Publicat: (2014)